Study summary
A new class of antibodies has reached phase 3 in Crohn's
26% vs 12%had visible gut healing on tulisokibart, against the rate expected without it
What was tested
Antibodies that block TL1A, a signal involved in both inflammation and scarring of the gut. Three are in late trials: tulisokibart, afimkibart and duvakitug.
What they found
- In an early Crohn's study, 26% had healing seen on endoscopy, against a historical figure of 12%. There was no placebo group.
- In ulcerative colitis, the maker of tulisokibart said its phase 3 trial met its goals, without yet releasing the data.
- Because TL1A also drives scarring, these drugs might prevent narrowing of the gut, which no current drug does.
What it means
The most watched new mechanism in Crohn's. Phase 3 results start arriving in 2028.
Last reviewed 2026-11-14 by the Find a Trial editorial team.
Information on this page is for educational purposes and is not medical advice.
Always consult qualified healthcare professionals about clinical trial participation.